 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] The US International Trade Commission (ITC) lawsuit between Medytox and Hugel, a botulinum toxin company, is expected to begin in earnest.
According to the government and related industries on the 17th, the Ministry of Trade, Industry and Energy held a specialized committee meeting on the 11th and approved the transfer of data that analyzed the sequencing of the strains of both companies. The final transfer will be decided by the Industrial Technology Protection Committee, but it is known to follow the decision of the expert committee.
Botulinum toxin is a state-managed resource that needs approval from the Minister of Industry when it is released overseas. The deadline for submitting ITC evidence is the 21st of this month.
Medytox filed a complaint with the ITC in March last year, accusing Hugel of stealing the strain. Hugel immediately protested, saying the source of the strain was different. The genetic sequence of the two strains is expected to play a crucial role in identifying the source of the strains. If the base sequence is the same, Medytox's argument will be bolstered, and if it is different, Hugel's argument will be bolstered. The ITC ruling is also likely to affect domestic lawsuits.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
